

Technology Appraisal Committee Meeting (Committee A)

Minutes: Confirmed

Date and Time: Tuesday 13 February 2018, 10.00 – 12.25

Venue: Prospero House
241 Borough High Street
London
SE1 1GA

| | | |
|-----------------|--|-----------------------|
| Present: | 1. Jane Adam (Chair) | Present for all notes |
| | 2. Dr Graham Ash | Present for all notes |
| | 3. Dr Jeremy Braybrooke | Present for all notes |
| | 4. Dr Justin Daniels | Present for all notes |
| | 5. Dr Steve Edwards | Present for all notes |
| | 6. Mr David Evans | Present for all notes |
| | 7. Dr Rita Faria | Present for all notes |
| | 8. Mr Adrian Griffin | Present for all notes |
| | 9. Dr Mohit Sharma | Present for all notes |
| | 10. Mrs Sarah Parry | Present for all notes |
| | 11. Mr Stephen Sharp | Present for all notes |
| | 12. Dr Brian Shine | Present for all notes |
| | 13. Professor Iain Squire (Vice Chair) | Present for all notes |
| | 14. Dr John Watkins | Present for all notes |

In attendance:

| | | |
|-----------------------|--|-----------------------|
| Rebecca Albrow | Technical Adviser, National Institute for Health and Clinical Excellence | Present for all notes |
| Donna Barnes | Project Manager, National Institute for Health and Care Excellence | Present for all notes |
| Meindert Boysen | Programme Director, National Institute for Health and Care Excellence | Present for all notes |
| Professor Peter Clark | CDF Clinical Lead, NHS England | Present for all notes |
| Henry Edwards | Technical Adviser, National Institute for Health and Care Excellence | Present for all notes |
| Thomas Feist | Project Manager, National Institute for Health and Care Excellence | Present for all notes |

| | | |
|-----------------|---|---------------------------|
| Sabine Grimm | ERG representative, Kleijnen Systematic Reviews Ltd | Present for notes 1 to 14 |
| Dr Rob Riemsma | ERG representative, Kleijnen Systematic Reviews Ltd | Present for notes 1 to 14 |
| Janet Robertson | Associate Director, National Institute for Health and Care Excellence | Present for all notes |
| Thomas Walker | Technical Analyst, National Institute for Health and Care Excellence | Present for all notes |

Non-public attendees:

| | | |
|---------------------|------------------------|---------------------------|
| Sarah Lawton | Public Health England | Present for all notes |
| Carrie Pailthorpe | Public Health England | Present for all notes |
| Ria Skelton | NICE, Editors | Present for all notes |
| Ana Uribe-Echeverry | NICE, Corporate Office | Present for notes 1 to 14 |

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisal of pembrolizumab for treating relapsed or refractory classical Hodgkin's lymphoma.
2. The Chair welcomed Dr Steve Edwards to his first meeting as a member of the Appraisal Committee.
3. The Chair informed the Committee of the non-public observers at this meeting: Sarah Lawton, Carrie Pailthorpe, Ria Skelton and Ana Uribe-Echeverry.
4. Apologies were received from Dr Minal Bakhai, Dr Rachel Hobson, Professor John McMurray, Ms Pamela Rees, Dr Paul Robinson, Ms Ellen Rule, and Professor Olivia Wu.

Appraisal of pembrolizumab for treating relapsed or refractory classical Hodgkin's lymphoma.

Part 1 – Open session

5. The Chair welcomed the invited experts, Professor Peter Clark, Sabine Grimm, and Dr Rob Riemsma, to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Merck Sharp & Dohme to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Dr Jane Adam, Dr Graham Ash, Dr Jeremy Braybrooke, Dr Justin Daniels, Dr Steve Edwards, Mr David Evans, Dr Rita Faria, Mr Adrian Griffin, Mrs Sarah Parry, Dr Mohit Sharma, Mr Stephen Sharp, Dr Brian Shine, and Dr John Watkins all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating relapsed or refractory classical Hodgkin's lymphoma.
 - 7.2. Professor Iain Squire declared a personal non-specific non-financial interest as he is an investigator on a clinical trial in heart failure sponsored by the company. The payment for this work goes to his employer.
 - 9.2.1 It was agreed that this declaration would not prevent Professor Iain Squire from participating in this section of the meeting.
 - 7.3. Dr Paul Robinson was absent due to a specific financial interest as he works for the company Merck Sharp and Dohme. It was agreed that this declaration would prevent Dr Paul Robinson from participating in this section of the meeting.
8. The Chair asked all NICE Staff to declare any relevant interests.
 - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating relapsed or refractory classical Hodgkin's lymphoma.
9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating relapsed or refractory classical Hodgkin's lymphoma.
10. The Chair introduced the main issues arising from the additional information that the company had submitted following the first committee discussion of pembrolizumab for treating relapsed or refractory classical Hodgkin's lymphoma.
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the

confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2a – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

Part 2b – Closed session

15. The Committee continued to discuss the clinical and cost effectiveness of pembrolizumab for treating relapsed or refractory classical Hodgkin's lymphoma.
16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

17. Wednesday 14 March, from 10.00am and to 5.00pm at National Institute of Health and Care Excellence, 10 Spring Gardens, SE1 1GA